Keros Therapeutics, Inc. (KROS) financial statements and ratios from SEC XBRL: revenue $243.86M (TTM), net margin 35.7%, revenue growth 6769.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $243.86M |
| Net Margin | 35.7% |
| Revenue Growth (YoY) | 6769.4% |
| EPS Growth (YoY) | -146.8% |
| FCF Growth (YoY) | -165.1% |
| Price / Book | 0.84 |
| Price / Sales | 15.46 |
| FCF Yield | -14.3% |
| DCF Value (model) | $234.92 |
| DCF Upside vs Price | 2024.1% |
| Altman Z-Score | 4.18 (safe) |
| Sector P/E (Healthcare) | 21.7 |
KROS overview · KROS earnings · KROS KPIs · KROS investor relations · KROS ownership · KROS peers · KROS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.